Clay Siegall Discusses His Company, Seattle Genetics


Clay Siegall is the CEO of Seattle Genetics and he gave an interview with Inspirery. He discussed how he got into the business because he has always been interested in the power of technology and medicine. He explained how he became interested in cancer treatment after one of his family members got sick and the treatment regimen they were placed on was rough.

Clay Siegall also discussed how his company makes money, with one of them being selling their own proprietary drugs. His company generates revenues via production partnerships and licensing processes and technologies that they have developed. As for when the company became profitable, that happened about 10 years after their initial public offering.

He talked about how great his company’s sales staff is and credits them with helping them land their first customer. He praised his staff, saying they have extensive knowledge of the products they sell. He continued to describe salespeople as being the face of the company.

About Clay Siegall

Doctor Siegall is the co-founder of Seattle Genetics. He serves as the company’s president, as well as the CEO and chairman of the board of directors. He co-founded the company back in 1998, and since then he has led the company to build a diverse line of therapies for cancer. Not only that, but Siegall led the company’s funding activities, and in 2001 he spearheaded its initial public offering. As a result of his leadership, the company has secured over $600 million via both private and public financings.

Before finding Seattle Genetics, he worked with the Bristol Myers Squibb Pharmaceutical Research Institute. He stayed there for six years, and he also worked with the National Institutes of Health for a few years. The doctor has authored more than 50 publications and he currently holds 15 patents.

As for education, he graduated from the George Washington University with a Ph.D. in genetics. He also holds a bachelor’s degree in zoology, which he earned from the University of Maryland.